The increasing cases of coronary artery disease and diabetes coupled with growing obesity globally are driving the market growth. On top of that, growing awareness related to heart conditions, technological advancement in treatments, and rising numbers of hospitals and healthcare infrastructure around the globe have propelled the myocardial ischemia market expansion. Moreover, strong economic growth, disposable incomes of patients, and improved standard of living can fuel the market growth over the forecast period.
The Myocardial Ischemia Treatment Market is expected to register a CAGR of 6.00%and is anticipated to reach USD 50,120.3 Million by 2023
Growing trend in the myocardial ischemia market is increasing usage of myocardial perfusion imaging. It is a stress test which relies on imaging of a patient’s heart before and after physical activity to determine the effects of stress on the flow of blood through the coronary arteries and the heart muscle.
Global Market for Myocardial Ischemia – Segmental Analysis
The global myocardial ischemia market is segmented on the basis of type, diagnosis & treatment, and end-user.
By type, the market is segmented on the basis of symptomatic and asymptomatic. The asymptomatic (silent) myocardial ischemia segment accounted for the largest market share in 2017. Growing number of smokers, family history of heart diseases, prevalence of cases of high cholesterol and high blood pressure, and lack of exercise can drive the growth in the segment.
By treatment & diagnosis, the market is segmented into treatment and diagnosis. The diagnosis segment is sub-segmented into imaging and stress test. On the other hand, the treatment segment is sub-segmented into medications and surgery. The treatment segment has gained significant traction owing to increasing prevalence of coronary heart disease and large population leading a stressful lifestyle. Thus, the treatment segment is estimated to hold largest market share till the end of the forecast period.
Key Players of the market
· Taxus Cardium (US),
· ViroMed Co. Ltd. (Republic of Korea ),
· Edward Lifesciences (US),
· Daiichi Sankyo Company Limited (Japan),
· Boston Scientific Corporation (US),
· Merck KGaA (Germany),
· Novartis AG (Switzerland),
· Boehringer Ingelheim International GmbH (Germany),
· Johnson & Johnson Services Inc. (US),
· Bayer AG (Germany),
· AstraZeneca (UK).
Access the full report @ https://www.marketresearchfuture.com/reports/myocardial-ischemia-market-5811
Regional Outlook
Geographically, the global myocardial ischemia market is spread across the Americas, Europe, Asia Pacific, and the Middle East and Africa.
MRFR noted that the Americas accounted for the largest market share and will maintain its dominance throughout the forecast period. The Americas market is presumed to reach USD 18,130.3 million by 2023 at a CAGR of 6.21% from 2017 to 2023. This position was achieved due to rising prevalence of diabetes, obesity, lack of physical inactivity, and excessive alcohol consumption among the population in the region.
After America, Europe holds the largest market share owing to high number of cases related to cardiovascular diseases. Revolutionary technology, rising healthcare infrastructure, continuous researches conducted to enhance treatment procedures, and easy access to medical facilities and medication has led to market growth in the region. Moreover, obesity and stressful schedules have given way to expansion of the market considerably.
About Us:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.